Effectiveness of Inspiratory Muscle Training in Patient With Stable Angina

Sponsor
Mustafa Kemal University (Other)
Overall Status
Completed
CT.gov ID
NCT03923153
Collaborator
(none)
40
1
2
16.5
2.4

Study Details

Study Description

Brief Summary

Stable angina is a cardiac pathology that adversely affects the quality of life of the patient, which develops as a result of narrowing of the coronary vessels developing in atherosclerotic ground and / or impaired oxygen supply-need balance. Studies widely investigated the effects of exercise training in patients with stable angina. No study investigated the effects of inspiratory muscle training in patients with stable angina.Investigators aimed to investigate the effects of inspiratory muscle training on aerobic exercise capacity, quality of life, depression, peripheral and respiratory (MIP, MEP) muscle strength, pulmonary function, dyspnea, fatigue in stable angina patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)
  • Device: Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)
N/A

Detailed Description

Patients with stable angina will be included. Primary outcome measurement is inspiratory muscle strength, secondary outcomes are functional exercise capacity, peripheral muscle strength, pulmonary functions, maximal exercise capacity, fatigue, quality of life, depression.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Effectiveness of Inspiratory Muscle Training in Patient With Stable Angina
Actual Study Start Date :
Apr 15, 2019
Actual Primary Completion Date :
Aug 30, 2020
Actual Study Completion Date :
Aug 30, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Inspiratory muscle training group

Inspiratory muscle training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device

Device: Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)
Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP). The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload. The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.

Sham Comparator: Sham group

Sham group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device

Device: Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)
Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP). The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload. The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department.

Outcome Measures

Primary Outcome Measures

  1. Change of the Inspiratory and expiratory muscle strength (MIP, MEP) from baseline to 8 week [Baseline, after 8 week]

    Mouth pressure device( MicroRPM, Micro Medical England)

Secondary Outcome Measures

  1. Change from Baseline Functional exercise capacity at 8 week [Baseline, after 8 week]

    6 minute walking test

  2. Change from Pulmonary functions at 8 week [Baseline, after 8 week]

    Spirometry

  3. Fatigue [Baseline, after 8 week]

    Change from baseline Fatigue Severity Scale (FSS) (Turkish version of scale) at 8 weeek. Patient choose a number from 1 to 7 that indicates how much the patient agrees with each statement, where 1 indicates strong disagreement and 7 indicates strong agreement. A score of 4 or higher generally indicates severe fatigue

  4. Depression [Baseline,after 8 week]

    Change from baseline Montgomery Asberg Depression Rating Scale (MADRS) (Turkish version of scale) at 8 week. This assessment tool contains 10 items with a score from 0 to 6, thus the maximum score is 60. A higher score indicates a more severe depression.

Other Outcome Measures

  1. Quality life [Baseline, after 8 week]

    Change of baseline quality of life at 8 week .Short Form (SF-36) Health Survey (Turkish version of scale) The SF-36 is a 36 item questionnaire that measures eight multi-item dimensions of health: physical functioning (10 items) social functioning (2 items) role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), mental health (5 items), energy/vitality (4 items), pain (2 items), and general health perception (5 items). For each dimension item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • No contraindication for pulmonary physiotherapy

  • Anjina patients who are clinically stable

  • have no other disease that may affect respiratory function

  • Individuals who have the good cooperation

Exclusion Criteria:
  • Patients under the age of 18

  • Pregnancy

  • Active infection

  • Patients with known malignancies

  • patients without consent

  • known arrhythmia, dilated or hypertrophic cardiomyopathy, heart failure (EF <40%)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hatay Mustafa Kemal University Hatay Merkez Turkey 31010

Sponsors and Collaborators

  • Mustafa Kemal University

Investigators

  • Study Director: Aysel yıldız, assoc prof, Marmara University Faculty of Health Sciences
  • Study Chair: Irem Hüzmeli, Msc, Mustafa Kemal University
  • Principal Investigator: Oğuz Akkuş, assist prof, hatay mustafa kemal university Faculty of Medicine
  • Study Chair: Fatih Yalçın, Prof., hatay mustafa kemal university Faculty of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Irem Hüzmeli, lecturer, Mustafa Kemal University
ClinicalTrials.gov Identifier:
NCT03923153
Other Study ID Numbers:
  • MustafaKU 2
First Posted:
Apr 22, 2019
Last Update Posted:
May 6, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Irem Hüzmeli, lecturer, Mustafa Kemal University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2021